Completed PHASE1 INTERVENTIONAL 1-arm NCT03168035

Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

Sponsor: M.D. Anderson Cancer Center

Interventions NC-4016

Updated 6 times since 2017 Last updated: Feb 22, 2018 Started: Nov 30, 2013 Primary completion: Apr 30, 2017 Completion: Apr 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03168035, this PHASE1 trial focuses on Advanced Cancer and Lymphoma and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 6 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Mar 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Jul 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE1

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
NanoCarrier Co., Ltd.

Data source: NanoCarrier Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States